Nuvalent (NUVL) Competitors $75.74 +0.81 (+1.07%) As of 03:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVL vs. TEVA, SMMT, GMAB, VTRS, ASND, RDY, QGEN, MRNA, BBIO, and VRNAShould you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Nuvalent vs. Its Competitors Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories QIAGEN Moderna BridgeBio Pharma Verona Pharma PLC American Depositary Share Teva Pharmaceutical Industries (NYSE:TEVA) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends. Which has more volatility & risk, TEVA or NUVL? Teva Pharmaceutical Industries has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Do institutionals & insiders have more ownership in TEVA or NUVL? 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 10.2% of Nuvalent shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is TEVA or NUVL more profitable? Nuvalent has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -0.95%. Teva Pharmaceutical Industries' return on equity of 46.10% beat Nuvalent's return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-0.95% 46.10% 7.18% Nuvalent N/A -32.58%-30.14% Do analysts rate TEVA or NUVL? Teva Pharmaceutical Industries presently has a consensus target price of $24.71, suggesting a potential upside of 35.98%. Nuvalent has a consensus target price of $118.91, suggesting a potential upside of 57.18%. Given Nuvalent's higher probable upside, analysts clearly believe Nuvalent is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Nuvalent 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Which has higher valuation & earnings, TEVA or NUVL? Nuvalent has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.26-$1.64B-$0.16-113.59NuvalentN/AN/A-$260.76M-$4.90-15.44 Does the media prefer TEVA or NUVL? In the previous week, Teva Pharmaceutical Industries had 2 more articles in the media than Nuvalent. MarketBeat recorded 13 mentions for Teva Pharmaceutical Industries and 11 mentions for Nuvalent. Teva Pharmaceutical Industries' average media sentiment score of 1.36 beat Nuvalent's score of 1.14 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTeva Pharmaceutical Industries and Nuvalent tied by winning 8 of the 16 factors compared between the two stocks. Get Nuvalent News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVL vs. The Competition Export to ExcelMetricNuvalentMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.45B$3.09B$5.74B$9.78BDividend YieldN/A2.26%4.40%4.04%P/E Ratio-15.4121.2030.8326.45Price / SalesN/A207.29383.3887.13Price / CashN/A44.2437.7259.11Price / Book5.818.0810.106.65Net Income-$260.76M-$54.08M$3.26B$265.42M7 Day Performance3.29%4.03%3.74%3.58%1 Month Performance-7.08%3.03%3.86%0.56%1 Year Performance-10.24%6.72%37.87%19.63% Nuvalent Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVLNuvalent3.3695 of 5 stars$75.74+1.1%$118.91+57.0%-10.9%$5.46BN/A-15.4640News CoverageTEVATeva Pharmaceutical Industries3.2233 of 5 stars$18.08+1.2%$24.71+36.7%-2.3%$20.48B$16.63B-113.0036,830Positive NewsSMMTSummit Therapeutics2.1912 of 5 stars$26.29-1.5%$35.00+33.1%+103.6%$19.83B$700K-26.03110Analyst ForecastGap DownGMABGenmab A/S3.6858 of 5 stars$23.42+0.5%$37.60+60.5%-10.3%$14.95B$3.12B11.772,682News CoverageVTRSViatris1.9188 of 5 stars$10.63+0.2%$10.40-2.2%-11.4%$12.37B$14.74B-3.6732,000ASNDAscendis Pharma A/S3.4129 of 5 stars$194.08-2.1%$242.93+25.2%+42.0%$12.13B$490.75M-37.611,017Positive NewsRDYDr. Reddy's Laboratories3.0652 of 5 stars$14.26+0.2%$16.95+18.9%-13.7%$11.87B$3.81B21.6027,811News CoverageQGENQIAGEN4.003 of 5 stars$48.66-1.4%$49.69+2.1%+11.3%$10.97B$1.98B28.755,765News CoveragePositive NewsMRNAModerna4.4987 of 5 stars$28.09+0.2%$43.59+55.2%-69.7%$10.90B$3.24B-3.735,800BBIOBridgeBio Pharma4.2887 of 5 stars$49.02-4.5%$61.35+25.2%+88.7%$9.81B$221.90M-11.99400VRNAVerona Pharma PLC American Depositary Share2.4814 of 5 stars$105.79+0.5%$109.00+3.0%+295.9%$8.96B$42.28M-106.8630Positive News Related Companies and Tools Related Companies TEVA Competitors SMMT Competitors GMAB Competitors VTRS Competitors ASND Competitors RDY Competitors QGEN Competitors MRNA Competitors BBIO Competitors VRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NUVL) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvalent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access